SIR has been successful as it has met an unmet clinical need in...

SIR has been successful as it has met an unmet clinical need in the treatment of colorectal metastases of the liver. Most of the patients suffering from liver metastases are palliative. This means SIR, despite its risk profile, is seen as a viable treatment for extending life. It is another option for clinicians to treat a cancer that did not previously exist and potentially extend life. Other embolics (eg TACE) are used to treat primary tumours - i.e. non malignancies.

FYI - SIR is delivered embolically via the hepatic artery. It is a risky procedure as there is a risk that the particles can migrate past the liver to other parts of the body. But the risk is acceptable given the patients have malignant cancer and are likely to pass away regardless. SIR is a life extending - not a curative treatment.... look how well it has done regardless of this. There is value in treatments that can extend life and provide clinicians with new tools to combat difficult to treat cancers.

The same can be said for OSL. There are very limited treatments available for pancreatic cancer. Surgical resection (whipples) has very high post-operative morbidity rates - it is life changing. Drugs have limited utility. The reason pancreatic cancer's morbidity rates are so high, is that they can not detect them early enough for less radical treatments to make an impact.

Clinicians will embrace a product that can give a patient a chance of increased life-expectancy, especially if it is minimally invasive and preserves other treatment options. OSL appears to meet many of these criteria, with the added benefit that it improves QoL by reducing a patient's pain (this was demonstrated in the early clinical data presented by the company).

It is not a perfect treatment, but, there are limited options for treating pancreatic cancer and a clinical need for new therapeutic options that OSL appears to fit.